Novo Holdings Acquires The Ritedose Corporation

Vireo Growth Inc to Acquire Certain Assets of The Cannabist Company Holdings Inc

July 20, 2026

Healthcare Services

Vireo Growth Inc, through its subsidiary Vireo Health of Arcadia, LLC, entered into a definitive purchase agreement to acquire certain cannabis cultivation, manufacturing, and retail operations from subsidiaries of The Cannabist Company Holdings Inc across Colorado, Illinois, Massachusetts, New Jersey, and West Virginia. The deal consideration is up to US$35 million (subject to regulatory approvals), with closing expected in stages through 2026 and 2027. Vireo expects the transaction to add up to 25 dispensaries and strengthen its vertically integrated presence in multiple limited-license cannabis markets.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.

Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Biotechnology

Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.

SP Industries (Harbour Group) Acquires i-Dositecno

October 31, 2019

Manufacturing

SP Industries, a Harbour Group company, acquired Irta Dosificacio I Technologia S.L. (i-Dositecno), a Spain-based provider of sterile liquid filling lines for pharmaceutical, cosmetic and ophthalmic applications. The acquisition (terms undisclosed) expands SP Industries' fill-finish product portfolio and adds i-Dositecno's European and Asian footprint and engineering/service capabilities to better serve global customers.